Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )
Authors' conclusion
Individuals with overweight or obesity prioritise weight-loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.
Study context
- Population
- US adults with obesity or overweight and ≥ 1 obesity-related complication; 400 obesity medication (OM)-naïve/400 OM-experienced, 400 injection-naïve/400 injection-experienced
- Participants
- 800 adults
- Exposure
- Treatment A vs Treatment B
- Outcome
- Relative importance of attributes driving OM choice and preferences
Methodological detailsonline survey, random-parameters logit model, fixed-choice comparison, Online survey conducted October-November 2025
- Online survey
- Random-parameters logit model
- Fixed-choice comparison
- Online survey conducted October-November 2025
Main finding
As reported in the abstract
Relative importance of OM attributes
- Most important attributes: route of administration, average weight-loss percentage, cardiovascular (CV) risk reduction, and proportion achieving ≥ 20% weight loss
- Dosing instructions had the lowest relative importance
Observational data: associations, not effects.
Further findings
Predicted preference for OM profile (DCE)
Preference for OM profile (fixed-choice question)
Taking OM on an empty stomach and waiting 30 min to eat would be disruptive
- Indicated disruptive to their lives
- 23.4%
OM-naïve participants open to taking an oral OM
- Open to oral OM (OM-naïve)
- 73.3%
Original publication
Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC ). Diabetes Obes Metab. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →